Businessteam

According to biospace.com, Endo Pharmaceuticals acquired Par Pharma for $8.05 billion. In the article, the CEO of Endo Pharmaceuticals says: “This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A.” For more information, visit: https://www.biospace.com/article/endo-pharmaceuticals-continues-expansion-with-8-05-billion-acquisition-of-par-pharma-/